RS60556B1 - Kondenzovani benzazepini za lečenje mucanja - Google Patents

Kondenzovani benzazepini za lečenje mucanja

Info

Publication number
RS60556B1
RS60556B1 RS20200880A RSP20200880A RS60556B1 RS 60556 B1 RS60556 B1 RS 60556B1 RS 20200880 A RS20200880 A RS 20200880A RS P20200880 A RSP20200880 A RS P20200880A RS 60556 B1 RS60556 B1 RS 60556B1
Authority
RS
Serbia
Prior art keywords
stuttering
treatment
fused benzazepines
benzazepines
fused
Prior art date
Application number
RS20200880A
Other languages
English (en)
Inventor
Richard E Chipkin
Original Assignee
Emalex Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emalex Biosciences Inc filed Critical Emalex Biosciences Inc
Publication of RS60556B1 publication Critical patent/RS60556B1/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
RS20200880A 2013-10-18 2014-10-17 Kondenzovani benzazepini za lečenje mucanja RS60556B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361892841P 2013-10-18 2013-10-18
PCT/US2014/061080 WO2015058053A1 (en) 2013-10-18 2014-10-17 Fused benzazepines for treatment of stuttering
EP14854586.6A EP3057595B1 (en) 2013-10-18 2014-10-17 Fused benzazepines for treatment of stuttering

Publications (1)

Publication Number Publication Date
RS60556B1 true RS60556B1 (sr) 2020-08-31

Family

ID=52828726

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20200880A RS60556B1 (sr) 2013-10-18 2014-10-17 Kondenzovani benzazepini za lečenje mucanja

Country Status (18)

Country Link
US (1) US9949983B2 (sr)
EP (1) EP3057595B1 (sr)
JP (3) JP2016533374A (sr)
AU (1) AU2014337140B2 (sr)
CA (1) CA2927915C (sr)
CY (1) CY1123121T1 (sr)
DK (1) DK3057595T3 (sr)
ES (1) ES2805448T3 (sr)
HR (1) HRP20201152T1 (sr)
HU (1) HUE049848T2 (sr)
IL (1) IL245155B (sr)
LT (1) LT3057595T (sr)
MX (1) MX370612B (sr)
PL (1) PL3057595T3 (sr)
PT (1) PT3057595T (sr)
RS (1) RS60556B1 (sr)
SI (1) SI3057595T1 (sr)
WO (1) WO2015058053A1 (sr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2872145T1 (sl) 2012-07-12 2022-07-29 Emalex Biosciences, Inc. Taljeni benzazepini za zdravljenje Tourettovega sindroma
EP3628316A4 (en) 2017-03-30 2021-04-14 Penello Temporão, José Eduardo MULTI-VITAMIN COMPOSITION TO IMPROVE VERB FLUIDITY AND REDUCE SYMPTOMS OF PERFORMANCE ANXIETY AND ITS PREPARATION PROCESS
AU2018274767A1 (en) * 2017-05-25 2020-01-30 Glytech Llc. Combined therapy for NMDAR antagonist-responsive neuropsychiatric disorders
US10786495B2 (en) * 2017-10-10 2020-09-29 The Regents Of The University Of California Vesicular monoamine transporter 2 inhibitors for treating stuttering
US20220257560A1 (en) * 2019-05-23 2022-08-18 India Globalization Capital, Inc. Compositions and methods using cannabinoids for treating stammering/stuttering and symptoms of tourette syndrome

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4477378A (en) 1980-02-05 1984-10-16 Schering Corp. Esters of substituted 8-hydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines
US4973586A (en) 1986-01-16 1990-11-27 Schering Corporation Fused benzazepines, compositions of, and medical use thereof
US5302716A (en) 1986-01-16 1994-04-12 Schering Corporation Fused benzazepines
BE1005064A4 (nl) 1991-07-03 1993-04-06 Asm Fico Tooling Buiginrichting.
GB9127306D0 (en) 1991-12-23 1992-02-19 Boots Co Plc Therapeutic agents
AU1945495A (en) 1994-03-16 1995-10-03 Novo Nordisk A/S Acid addition salts of 2,3,4,5-tetrahydro-1h-3-benzazepine compounds
AU1110099A (en) 1997-10-28 1999-05-17 Schering Corporation Method of reducing craving in mammals
US6132724A (en) * 1998-04-29 2000-10-17 City Of Hope National Medical Center Allelic polygene diagnosis of reward deficiency syndrome and treatment
SE9904724D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
US8518933B2 (en) * 2009-04-23 2013-08-27 Abbvie Inc. Modulators of 5-HT receptors and methods of use thereof
US20110206782A1 (en) * 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor
WO2012033874A1 (en) 2010-09-10 2012-03-15 Chipkin Richard E Method of treating compulsive self-injurious behaviors
SI2872145T1 (sl) 2012-07-12 2022-07-29 Emalex Biosciences, Inc. Taljeni benzazepini za zdravljenje Tourettovega sindroma

Also Published As

Publication number Publication date
MX2016005030A (es) 2017-01-23
NZ719103A (en) 2021-05-28
HRP20201152T1 (hr) 2020-10-30
IL245155B (en) 2020-07-30
AU2014337140B2 (en) 2020-01-30
MX370612B (es) 2019-12-18
IL245155A0 (en) 2016-06-30
CA2927915A1 (en) 2015-04-23
EP3057595B1 (en) 2020-04-29
EP3057595A4 (en) 2017-06-07
EP3057595A1 (en) 2016-08-24
US9949983B2 (en) 2018-04-24
CY1123121T1 (el) 2021-10-29
PL3057595T3 (pl) 2021-03-08
LT3057595T (lt) 2020-08-10
AU2014337140A1 (en) 2016-05-12
JP2019147843A (ja) 2019-09-05
ES2805448T3 (es) 2021-02-12
CA2927915C (en) 2021-10-26
DK3057595T3 (da) 2020-08-10
JP7245509B2 (ja) 2023-03-24
SI3057595T1 (sl) 2020-09-30
WO2015058053A1 (en) 2015-04-23
PT3057595T (pt) 2020-07-31
HUE049848T2 (hu) 2020-11-30
US20160271141A1 (en) 2016-09-22
JP2021080288A (ja) 2021-05-27
JP2016533374A (ja) 2016-10-27

Similar Documents

Publication Publication Date Title
SG11201506876XA (en) Modification of polypeptides
AU352456S (en) Process tube
GB2519934B (en) Improved shisha
HK1216429A1 (zh) 用於純化芳基硫酸酯酶 的方法
GB2516725B (en) Neck Orthosis
IL245379A0 (en) Heterocyclic n-acylamino compounds
SG11201505204VA (en) Protein purification process
SG11201603028SA (en) Purification of proteins
EP3043813A4 (en) CLEANING CHIMERIC FVIII MOLECULES
IL245155B (en) Benzazepines are combined for the treatment of stuttering
EP3065944A4 (en) Modification of polyamides
GB2539112B (en) Chlorination of sucrose-6-esters
EP2929915A4 (en) CULTURISM DEVICE
GB201308466D0 (en) Improved process for treatment of minewater
IL244347A0 (en) n-acylamino heterocyclic compounds
ZA201601248B (en) Wheelchair
AU347055S (en) Jug
GB201303796D0 (en) Condom
GB201314581D0 (en) Purification
HK1217700A1 (zh) 多晶型物形式
GB2514324B (en) Modified tubular
GB201300649D0 (en) Cyclization
GB201301722D0 (en) Quantifcation of bacteria
GB201322366D0 (en) Chlorination of sucrose-6-esters
GB201314779D0 (en) Chlorination of sucrose-6-esters